Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
15 April 2021
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
Melanoma Institute Australia and Melanoma Patients Australia are partnering to develop the country’s first ever landmark melanoma report: State of the Nation – A Report into Melanoma.
This comprehensive report will examine the issues currently facing melanoma patients and carers across Australia and make recommendations for policy change and investment to substantially improve outcomes for them as well as the wider Australian community.
‘Australia has the highest melanoma rates in the world, and this State of the Nation report will for the first times provide an indepth assessment of the far-reaching impacts of the disease across the country,’ said Melanoma Institute Australia CEO Matthew Browne.
‘It will provide the opportunity to revolutionise melanoma policy, funding, care and support services going forward, which will in the long term benefit all Australians for generations to come.’
Critical to developing State of the Nation- A Report into Melanoma is input from melanoma patients and their carers from across Australia. This is a call to action and we are asking people to take part in an online survey so we can understand their personal experiences.
‘The survey will provide invaluable insights into the impact of melanoma and the realities faced by patients and their families,’ said Melanoma Patients Australia CEO Victoria Beedle.
‘Your feedback is critical to the success of this State of the Nation report and I urge all melanoma patients and their families to invest just half an hour in completing this survey. By doing so, you will become part of the solution to this huge problem impacting communities across the country.’
Key areas being addressed in State of the Nation- A Report into Melanoma include:
- melanoma prevention and awareness, including the effectiveness of current campaigns and what more needs to be done
- early detection and diagnosis including the feasibility of a national skin screening program
- treatment options available and access to breakthrough therapies
- supportive care services during and after treatment
- issues facing survivors and their families after successful treatment
- palliative and end of life care
- research priorities, opportunities and challenges.
The State of the Nation report will be presented to government mid-year with the aim of guiding future policy and funding direction to help reduce the impact of melanoma on Australian society.
‘Every 30 minutes another Australian is told they have melanoma – so in the time it takes you to do the survey, another family will be embarking on the daunting and frightening melanoma journey,’ Matthew Browne added.
‘Completing the survey is a small investment of time with a potentially life-changing impact, and I thank all our wonderful melanoma community for stepping up to help.’
Federal government urged
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
“I’m the age Emma was when she passed away. It almost feels
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.